Abstract Number: 1501 • 2014 ACR/ARHP Annual Meeting
Immunogenicity Assessment of PF-06438179, a Potential Biosimilar to Infliximab, in Healthy Volunteers
Background/Purpose: PF-06438179, a proposed biosimilar to infliximab, was evaluated for immunogenicity in a phase 1 pharmacokinetic (PK) similarity study. Methods: In this double-blind trial (NCT01844804),…Abstract Number: 1500 • 2014 ACR/ARHP Annual Meeting
Preclinical and Clinical Characterization of MK-8457, a Selective Spleen Tyrosine Kinase and Zeta-Chain-Associated Protein Kinase 70 Inhibitor, in Normotensive and Hypertensive Cardiovascular Models
Background/Purpose: Spleen Tyrosine Kinase (SYK) and Zeta-chain-associated protein kinase 70 (ZAP70) are non-receptor protein kinases that bind phosophorylated receptor tyrosine-based activation motifs, critical in immune…Abstract Number: 1499 • 2014 ACR/ARHP Annual Meeting
Characterization of ABT-494, a Second Generation Jak1 Selective Inhibitor
Background/Purpose Jak kinase blockade can effectively manage rheumatoid arthritis (RA) and in some cases achieve remission. However, first generation Jak inhibitors have not met expectations…Abstract Number: 1498 • 2014 ACR/ARHP Annual Meeting
ALX-0061, an Anti-IL-6R Nanobody® for use in Rheumatoid Arthritis, Demonstrates a Different in Vitro Profile As Compared to Tocilizumab
Background/Purpose Interleukin-6 (IL-6) is a pleiotropic cytokine inducing a wide range of biological activities via its receptor, which can either be soluble (sIL-6R) or membrane-bound…Abstract Number: 1497 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Iguratimod for Rheumatoid Arthritis
Background/Purpose: Iguratimod is a new small-molecular drug for rheumatoid arthritis (RA), which was approved on June, 2012 in Japan. The agent inhibits the production of…Abstract Number: 1496 • 2014 ACR/ARHP Annual Meeting
Exposure-Response Analysis for Mavrilimumab Phase2b Study in RA Patients with Informative Dropout
Background/Purpose: Mavrilimumab is a recombinant human monoclonal antibody which neutralizes granulocyte-macrophage colony stimulating factor (GM-CSF) activity by selectively binding to the alpha subunit of its…Abstract Number: 1495 • 2014 ACR/ARHP Annual Meeting
Preclinical and Clinical Phase I Profile of MK-8457, a Selective Spleen Tyrosine Kinase and Zeta-Chain-Associated Protein Kinase 70 Inhibitor, Developed for the Treatment of Rheumatoid Arthritis
Background/Purpose: Spleen tyrosine kinase (SYK) is a potential target for treatment of several diseases including rheumatoid arthritis. SYK is a member of the Zeta-chain-associated protein…Abstract Number: 1494 • 2014 ACR/ARHP Annual Meeting
Treatment of Rheumatoid Arthritis Patients with the JAK1-Selective Inhibitor GLPG0634 Reverses an Arthritis-Specific Blood Gene Signature to Healthy State
Background/Purpose The 4 Janus kinases (JAK1, JAK2, JAK3 and TYK2) are cytoplasmic tyrosine kinases that mediate intracellular signaling of cytokines (e.g. certain interleukins and interferons)…Abstract Number: 1493 • 2014 ACR/ARHP Annual Meeting
A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF1R) Antibody in Healthy Volunteers and Subjects with Rheumatoid Arthritis (RA): Preliminary Results
Background/Purpose Activation of CSF1R via IL34 or CSF1 results in activation, differentiation, and survival of monocytes, macrophages and osteoclasts. CSF1R activation produces inflammatory cytokines responsible…Abstract Number: 1491 • 2014 ACR/ARHP Annual Meeting
Discovery and Characterization of COVA322, a Clinical Stage Bispecific TNF/IL-17A Inhibitor for the Treatment of Inflammatory Diseases
Background/Purpose: Biologics such as TNF inhibitors have revolutionized the treatment of inflammatory diseases including rheumatoid arthritis (RA), psoriasis and psoriatic arthritis. However, recent data suggest that…Abstract Number: 1490 • 2014 ACR/ARHP Annual Meeting
Can Tumor Necrosis Factor Inhibitors Protect Rheumatoid Arthritis Patients from Osteoporosis? Impact of Tumor Necrosis Factor Inhibitors on Bone Mineral Density and Bone Remodeling Markers
Background/Purpose Rheumatoid Arthritis (RA) is a chronic inflammatory disease characterized by joint and bone destruction. Loss of bone in RA is not only localized in…Abstract Number: 1489 • 2014 ACR/ARHP Annual Meeting
Influences of Disease Activity at the Initiation of Iguratimod, a Small Molecule Antirheumatic Drug, on Efficacy of Iguratimod in Patients with Rheumatoid Arthritis –a Multicenter Registry Study-
Background/Purpose: Iguratimod (IGU), known as T-614, is a small-molecule antirheumatic drug developed in Japan and used in Japanese clinical practice since June in 2012. IGU…Abstract Number: 1487 • 2014 ACR/ARHP Annual Meeting
A Phase 1 Dose-Ranging Repeated-Dose Trial of Parenteral Staphylococcal Protein A (PRTX-100) in Patients with Active Rheumatoid Arthritis on Methotrexate or Leflunamide Therapy
Background/Purpose Staphylococcal protein A (SpA) binds with high affinity to the Fc region of human immunoglobulin G and also to the Fab framework region of…Abstract Number: 1492 • 2014 ACR/ARHP Annual Meeting
Safety and Tolerability of NNC01140006, an Anti-IL-21 Monoclonal Antibody, at Multiple s.c. Dose Levels in Patients with Rheumatoid Arthritis
Background/Purpose A phase 1, randomised, double-blind, placebo-controlled, dose-escalation trial was conducted to assess the safety and tolerability of the anti-IL-21-antibody NNC0114-0006, in patients with active…Abstract Number: 1472 • 2014 ACR/ARHP Annual Meeting
Synovial Fluid from Rheumatoid Arthritis Patients Modulates the Immunophenotype and Viability of Monocytes
Background/Purpose Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by infiltration of the synovium by inflammatory cells that destroys the cartilage and the…
ACR Meeting Abstracts